Solara Active Pharma Sciences appoints Poorvank Purohit as MD & CEO

Poorvank Purohit

Pharmaceuticals company Solara Active Pharma Sciences Limited announced the appointment of Poorvank Purohit as Managing Director and Chief Executive Officer of the company, with effect from July 5, 2023.

According to the company’s exchange filing, “The Board of Directors of the Company, pursuant to the recommendation by the Nomination and Remuneration Committee, approved the appointment of Mr. Poorvank Purohit as Managing Director & CEO of the Company with effect from July 5, 2023, subject to the approval of the shareholders of the Company.”

Poorvank Purohit has over 19 years of strong B2B experience in both API & Finished Dosage Forms. He is known as a transformational leader which are endorsed with his award of being ‘’Person of the Year 2021” by Inner Review Magazine (March 2022 edition) and being featured among ‘’Top 10 Chief Operating Officers 2021’’ across sectors by CEO Insights Magazine (September 2021 edition). His expertise lies in turning around companies for exponential growth and sustainable organization. Poorvank has built business across geographies with top Innovator/Generic/Dossier companies.

Poorvank is a Chemical Engineering graduate from M. S. Ramaiah Institute of Technology, Bangalore. An alumnus of IIMB and Wharton Business School, Poorvank has previously worked for leading pharma organizations viz Hikal, Alembic, Jubilant, Ranbaxy (Sun Pharma), R L Fine Chem (an API focused company) and has held leadership positions providing strategic direction and orchestrated business improvement programs.

Poorvank has joined Solara as Chief Executive Officer with effect from February 3, 2023.

+ posts

HrNxt.com Newsdesk has researchers and writers with an excellent domain knowledge about the talent ecosystem, and the business environment. The team keeps a tab on the latest happenings in the ecosystem to bring most relevant news and insights for our readers. You can connect with our newsdesk at newsdesk@hrnxt.com.

What's your take on this post ? Comment: